

Accreditation a new way

NATA/RCPA Human Pathology Re-Engineering:

Clinical Governance

Dr Michael Harrison, Managing Partner and CEO, SNP Past President RCPA Past MTAAC Chair

www.nata.com.au



Human Pathology Re-Engineering

Clinical Governance

Who's in charge here?

Who is the designated person?

Are they responsible for all aspects of the Medical Pathology Service?

Is there a clearly documented delegation structure?

Do they have the authority to address any risks to patient safety in the MPS?

Are all major incidents reported to them?



Human Pathology Re-Engineering

Clinical Governance

What do they do?

Demonstrate leadership in all areas of the MPS

Involvement in protocols for collection, patient ID, transport, SRA/DE

Review of QC and QA summary reports
Review of incidents

Review of workplace safety
Review of test/equipment validation
Review of staff performance



Human Pathology Re-Engineering

Clinical Governance

What about Networks?

Standardization is the key Common protocols Common equipment Divergence/anarchy is the enemy Cat GX lab must be pro-active Surveillance should be regular and enforced - including result review, QC & QA review and audits



Human Pathology Re-Engineering

Clinical Governance

Common deficiencies

Unclear responsibilities Lack of medical leadership Lack of standardization Turf battles/parochialism Loss of key personnel and associated decline in performance Poor reporting processes Lack of audit/surveillance

Thankyou

Andrew.Griffin@nata.com.au

Gillian.Treloar@nata.com.au

